Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

Liver International

Volumn 37, Issue 4, 2017, Pages 514-528

  Di Maio, V C ^x   Cento, Valeria ^a   Lenci, I ^x   Aragri, M ^x   Rossi, Piera ^b   Barbaliscia, S ^x   Melis, Michela ^c   Verucchi, G ^x   Magni, C F ^x   Teti, Elisabetta ^b   Bertoli, Ada ^a   Antonucci, FrancescoPaolo ^a   Bellocchi, Maria C ^a   Micheli, Valeria ^e   Masetti, Chiara ^b   Landonio, Simona ^e   Francioso, Simona ^b   Santopaolo, Francesco ^b   Pellicelli, A ^x   Calvaruso, Vincenza ^g   Gianserra, Laura ^h   Siciliano, Massimo ⁱ   Romagnoli, Dante ^j   Cozzolongo, R ^x   Vecchiet, J ^x   Morisco, Filomena ^m   Merli, Manuela ^h   Brancaccio, G ^x   Di Biagio, Antonio ^o   Loggi, Elisabetta ^p   Mastroianni, Claudio M ^h   Pace Palitti, Valeria ^q   Tarquini, Pierluigi ^r   Puoti, Massimo ^s   Taliani, Gloria ^h   Sarmati, Loredana ^b   Picciotto, Antonino ^t   Vullo, Vincenzo ^u   Caporaso, Nicola ^m   Paoloni, Maurizio ^v   Pasquazzi, Caterina ^h   Rizzardini, Giuliano ^e,w   Parruti, Giustino ^q   Craxì, Antonio ^g   Babudieri, Sergio ^c   Andreoni, Massimo ^b   Angelico, Mario ^b   Perno, Carlo F ^a   Ceccherini Silberstein, F ^x   Mariani, R ^x   Iapadre, N ^x   Grimaldi, A ^x   Andreone, P ^x   Menzaghi, B ^x   Quirino, T ^x   Pisani, V ^x   Torti, C ^x   Bruzzone, B ^x   De Maria, A ^x   Marenco, S ^x   Nicolini, L A ^x   Viscoli, C ^x   Casinelli, K ^x   Delle Monache, M ^x   Lichtner, M ^x   Aghemo, A ^x   Boccaccio, V ^x   Bruno, S ^x   Cerrone, M ^x   Colombo, M ^x   D'Arminio Monforte, A ^x   Danieli, E ^x   Donato, F ^x   Gubertini, G ^x   Lleo, A ^x   Mancon, A ^x   Monico, S ^x   Niero, F ^x   Russo, M L ^x   Gnocchi, M ^x   Orro, A ^x   Milanesi, L ^x   Baldelli, E ^x   Bertolotti, M ^x   Borghi, V ^x   Mussini, C ^x   Gaeta, G B ^x   Lembo, V ^x   Sangiovanni, V ^x   Di Marco, V ^x   Mazzola, A ^x   Petta, S ^x   D'Amico, E ^x   Cacciatore, P ^x   Consorte, A ^x   Pieri, A ^x   Polilli, E ^x   Sozio, F ^x   Antenucci, F ^x   Baiocchi, L ^x   Biliotti, E ^x   Biolato, M ^x   Carioti, L ^x   Cerasari, G ^x   Cerva, C ^x   Ciotti, M ^x   D'Ambrosio, C ^x   D'Ettorre, G ^x   De Leonardis, F ^x   De Sanctis, A ^x   Di Paolo, D ^x   Furlan, C ^x   Gallo, P ^x   Gasbarrini, A ^x   Giannelli, V ^x   Grieco, S ^x   Lambiase, L ^x   Lattanzi, B ^x   Lula, R ^x   Malagnino, V ^x   Manuelli, M ^x   Miglioresi, L ^x   Milana, M ^x   Moretti, A ^x   Nosotti, L ^x   Palazzo, D ^x   Romano, M ^x   Sarrecchia, C ^x   Sforza, D ^x   Sorbo, M C ^x   Spaziante, M ^x   Svicher, V ^x   Tisone, G ^x   Vespasiani Gentilucci, U ^x   D'Adamo, G ^x   Mangia, A ^x   Maida, I ^x   Mura, M S ^x   Falconi, L ^x   Di Giammartino, D ^x   more..

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^k NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^l Pathological Anatomy   (Italy)

^m UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁿ SECOND UNIVERSITY OF NAPLES   (Italy)

^o UNIVERSITY OF GENOA   (Italy)

^p UNIVERSITY OF BOLOGNA   (Italy)

^q Pescara General Hospital   (Italy)

^r Hospital G Mazzini   (Italy)

^s OSPEDALE NIGUARDA CA GRANDA   (Italy)

^t UNIVERSITY OF GENOA   (Italy)

^u SAPIENZA UNIVERSITY OF ROME   (Italy)

^v Neurosurgery Department   (Italy)

^w UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^x Faculty of Health Science University of the Witwatersrand ^*

more..

Author keywords

antiviral therapy; direct acting antivirals; hepatitis C virus; resistance test; resistance associated substitutions

Indexed keywords

ANTIVIRUS AGENT; ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; INTERLEUKIN 28; LEDIPASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; INTERFERON; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; AGED; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREVALENCE; RELAPSE; SANGER SEQUENCING; CHRONIC HEPATITIS C; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HEPACIVIRUS; ITALY; MULTICENTER STUDY; MUTATION; RECURRENT DISEASE; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE;

AGED; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; ITALY; MALE; MIDDLE AGED; MUTATION; RECURRENCE; RIBAVIRIN; SEQUENCE ANALYSIS, DNA; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; TREATMENT FAILURE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85016473450     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13327     Document Type: Article

References (41)

1. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017; 66:153–194.
2. Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C. http://www.hcvguidelines.org. Accessed September 16, 2016.
3. Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430–1441.
4. Krishnan P, Tripathi R, Schnell G, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445–5454.
5. Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3. Randomized study. Hepatology. 2016;64:370–380.
6. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2015;64:360–369.
7. Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–1505.
8. Pawlotsky JM, Hepatitis C. Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.
9. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med. 2010;2:30ra32.
10. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol. 2013;87:1544–1553.
11. Svarovskaia ES, Zeuzem S, Hedskog C, et al. Prevalence of pretreatment NS5A and NS5B resistance-associated variants and genetic variation within HCV subtypes across different countries/gilead-study. J Hepatol. 2015;62:S679.
12. Yoshimi S, Imamura M, Murakami E, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87:1913–1920.
13. Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. J Hepatol. 2015;62:S220.
14. Dvory-Sobol H, Wyles D, Ouyang W, et al. Long-term persistence of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir. J Hepatol. 2015;62:S221.
15. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504.
16. Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol. 2015;62:S192.
17. Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A-containing DAA regimens: results of the retreatment study. J Hepatol. 2016;64:S147.
18. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. Prevalence of resistance-associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501–512.
19. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13.
20. Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, Elbasvir, and Ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. Clin Infect Dis. 2016;62:32–36.
21. Hezode C, Chevaliez S, Scoazec G, et al. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016;63:1809–1816.
22. Vermehren J, Susser S, Dietz J, et al. Retreatment of patients who failed DAA-combination therapies: Real-world experience from a large hepatitis C resistance database. J Hepatol. 2016;64:S188.
23. Lontok E, Harrington P, Howe A, et al. Hepatitis C Virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.
24. European Association for Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63:199–236.
25. Craxi A, Perno CF, Vigano M, Ceccherini-Silberstein F, Petta S. From current status to optimization of HCV treatment: recommendations from an expert panel. Dig Liver Dis. 2016;48:995–1005.
26. Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015;63:1511–1522.
27. Ceccherini SF, Di MV, Aragri M, Ciotti M, Cento V, Perno CF. Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents. Hepatology. 2015;63:1058–1059.
28. Di Maio VC, Cento V, Di Paolo D, et al. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother. 2016;71:739–750.
29. Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology. 2013;444:329–336.
30. Kieffer TL, De MS, Bartels DJ, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE. 2012;7:e34372.
31. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–462.
32. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–1674.
33. Black S, Pak I, Ingravallo P, et al. Resistance analysis of virologic failures in hepatitis C genotype 1-infected patients treated with Grazoprevir + Elbasvir ± Ribavirin: the C-WORTHY study. J Hepatol. 2015;62:S620.
34. Hepatitis C. Guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62:932–954.
35. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383:515–523.
36. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–1877.
37. Andre-Garnier E, Ribeyrol O, Gournay J, et al. Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort. Antivir Ther. 2016;21:611–619.
38. Svarovskaia ES, Gane E, Dvory-Sobol H, et al. L159F and V321A sofosbuvir-associated hepatitis C virus NS5B substitutions. J Infect Dis. 2016;213:1240–1247.
39. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61:56–65.
40. Hezode C, Fourati S, Scoazec G, et al. Retreatment of HCV DAA failures: HCV infection may be incurable. J Hepatol. 2016;64:S400.
41. Poordad F, Bennett M, Sepe TE, et al. Ombitasvir/Paritaprevir/r, Dasabuvir, and sofosbuvir treatment of patients with HCV genotype 1-infection who failed a prior course of DAA therapy: the QUARTZ-I study. J Hepatol. 2016;64:S767.